Skip to main content
Premium Trial:

Request an Annual Quote

Marina Says microRNA Antagonists Effective in In Vivo Testing

Premium

Marina Biotech this week announced that it has conducted experiments in which its conformationally restricted nucleotide technology was used to produce microRNA antagonists capable of de-repressing targets of miR-122 in vivo.

The agent could trigger two-and-a-half-fold de-repression of the miRNA's targets at a dose of 10 mg/kg, while demonstrating “good tolerability with repeat dosing,” the company said.

The CRN technology essentially comprises nucleotide analogs to which the C2' and C4' carbon bonds of the ribose ring are linked. Marina has been touting its utility in the creation of efficient miRNA inhibitors for some time (GSN 7/14/2011).

"With the completion of this early work with our CRN chemistry, we now have in vivo demonstration of our ability to develop single-stranded oligonucleotide therapeutic compounds," Marina President and CEO Michael French said in a statement. "Further, we now have in vivo proof of concept across our entire nucleic acid-based therapeutic platform demonstrating the ability to silence gene targets through either RNA interference or translational blocking, or via a microRNA mimetic, and, in the case of these data, to up-regulate gene targets via a microRNA antagonist.”

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.